GLP-1 receptor agonists like semaglutide and tirzepatide produce weight loss that can exceed 15% of body mass, but a significant fraction of that loss, something like 30-50%, comes from lean tissue. For performance athletes, that number is unacceptable. The cardiovascular system remodels under training load, and rapid weight loss can disrupt that adaptation. Two growth-hormone-releasing hormone (GHRH) analogs, tesamorelin and CJC-1295, have emerged as potential tools to preserve muscle during a GLP-1 agonist cut. But they work through different mechanisms, and the choice between them matters for athletes who need to protect contractile tissue while shedding fat.
Why GLP-1 Agonists Threaten Muscle
GLP-1 receptor agonists suppress appetite and slow gastric emptying, creating a sustained caloric deficit. That deficit triggers proteolysis, and the body preferentially catabolizes muscle when energy intake drops sharply. Recent work (Sikiric 2018) showed elevated VEGF expression after certain peptide interventions, hinting that growth hormone pathways might offset some of this damage. But the GLP-1 drugs themselves do not directly spare muscle. They simply reduce intake, leaving the athlete in a catabolic state unless countermeasures are taken. The heart, too, adapts to weight loss with reductions in left ventricular mass, a change that can impair stroke volume during high-intensity efforts. So the question becomes: can a GHRH analog shift the ratio of fat loss to muscle loss, and if so, which one?
Tesamorelin: Pulsatile GH and IGF-1 Stability
Tesamorelin is a synthetic 44-amino-acid peptide that mimics endogenous GHRH. It binds the GHRH receptor on somatotrophs, triggering pulsatile growth hormone release. That pulsatility matters because it preserves the natural feedback loops that regulate IGF-1 production. In a study on HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue by something like 15% while preserving lean mass. For an athlete on a GLP-1 agonist, that profile is appealing. The peptide has a half-life of roughly 30 minutes, so it requires daily subcutaneous injection. Compliance is a factor, but the reward is a GH pulse that looks physiologically normal. Some athletes stack tesamorelin with hexarelin to amplify the GH pulse, though that combination introduces additional variables. The key point: tesamorelin does not flood the system with GH. It nudges the pituitary, and the resulting IGF-1 elevation, typically in the neighbourhood of 20-30%, may be enough to counteract the catabolic pull of a GLP-1 agonist.
CJC-1295: Prolonged GH Elevation and Desensitization Risk
CJC-1295 is a modified GHRH analog with a longer half-life, often reported at 6-8 days when conjugated with DAC (drug affinity complex). That extended activity means fewer injections, but it also produces a sustained GH elevation that does not mimic natural pulsatility. The pituitary can downregulate GHRH receptors under constant stimulation, a phenomenon observed in some animal models. For an athlete, that desensitization risk is not trivial. If the pituitary becomes less responsive, the peptide loses efficacy over time. Still, CJC-1295 has been studied in combination with ipamorelin, a ghrelin mimetic, to boost GH output. The synergy can push IGF-1 levels higher than tesamorelin alone, perhaps into the range of 50-70% above baseline. But that comes with a cost: higher IGF-1 may accelerate cell growth in tissues an athlete would rather not stimulate. The cardiovascular system, for instance, can develop pathological hypertrophy if IGF-1 signaling is too robust. So the choice between tesamorelin and CJC-1295 is partly a choice between a gentle, pulsatile signal and a more aggressive, sustained one.
Muscle Retention Mechanisms: IGF-1 and Beyond
Both peptides ultimately work through IGF-1, which activates the PI3K/Akt pathway to promote protein synthesis and inhibit proteolysis. But the story is more complicated. Growth hormone itself has direct lipolytic effects, mobilizing fatty acids from adipose tissue. That means a GHRH analog can simultaneously increase fat oxidation and spare muscle, a dual action that pairs well with a GLP-1 agonist. Some athletes also use tesamorelin to blunt muscle catabolism during overreaching phases, where the stress of high-volume training mimics the catabolic state of a caloric deficit. The overlap is instructive: if tesamorelin can preserve muscle when training load is extreme, it may do the same when energy intake is low. CJC-1295, with its longer half-life, might offer 24-hour protection, but the risk of receptor downregulation leaves an open question: does the sustained signal eventually become less effective than a daily pulse?
Cardiovascular Considerations for Athletes
The athletic heart adapts to endurance training with eccentric hypertrophy, increasing chamber size and stroke volume. Weight loss can reverse some of that adaptation, reducing left ventricular mass and impairing performance. IGF-1 is a key mediator of cardiac growth, and both tesamorelin and CJC-1295 can elevate IGF-1 enough to influence cardiac remodeling. The concern is not trivial: excessive IGF-1 can push the heart toward concentric hypertrophy, a stiffer, less compliant ventricle. For an athlete on a GLP-1 agonist, the goal is to preserve the athletic heart phenotype, not distort it. Tesamorelin's pulsatile GH release may be less likely to cause pathological remodeling because it mimics the natural secretory pattern. CJC-1295, with its sustained elevation, could theoretically produce a more constant IGF-1 signal, and constant signals often drive maladaptation. Research on post-workout recovery with these peptides suggests that timing matters: a GH pulse after training may enhance repair without chronic elevation. That principle likely extends to the GLP-1 agonist context.
Practical Comparisons: Half-Life, Dosing Frequency, and Stacking
Tesamorelin requires daily injections, typically before bed to align with the natural nocturnal GH surge. CJC-1295 with DAC can be injected once or twice weekly. For an athlete already managing GLP-1 agonist injections, the added burden of daily tesamorelin is real. But the pulsatile pattern may be worth the hassle. Some protocols stack tesamorelin with ipamorelin, a ghrelin receptor agonist, to amplify the GH pulse without extending its duration. That combination can push IGF-1 higher while preserving pulsatility. CJC-1295 is often stacked with ipamorelin for the same reason, but the long half-life of CJC-1295 means the pituitary is exposed to a continuous GHRH signal. Over weeks, that can lead to diminishing returns. Another peptide, IGF-1 LR3, bypasses the pituitary entirely and directly activates IGF-1 receptors. It is sometimes used as an alternative to GHRH analogs, but it carries a higher risk of hypoglycemia and organ growth. BPC-157, a peptide derived from gastric juice, does not elevate GH or IGF-1 but may accelerate healing of muscle microtears. It is not a direct muscle-sparing agent, but it can support recovery during a cut. The choice among these options depends on the athlete's risk tolerance and the specific demands of their sport.
Open Questions and the Road Ahead
No head-to-head trial has compared tesamorelin and CJC-1295 for muscle retention during GLP-1 agonist therapy. The existing data come from studies on HIV patients, growth hormone deficiency, and healthy volunteers. Extrapolating to athletes requires caution. The cardiovascular effects of these peptides, particularly on the athletic heart, are poorly characterized. We know that tesamorelin can accelerate recovery from exercise-induced muscle damage, but whether that translates to net muscle retention over months of caloric deficit is unproven. The same uncertainty applies to CJC-1295. For now, the decision rests on mechanistic reasoning: pulsatile GH release seems safer for long-term use, but the convenience of weekly dosing is seductive. What remains unknown is whether the pituitary downregulation seen with CJC-1295 in animals occurs in humans at the doses athletes would use, and whether that downregulation matters for muscle preservation. Until those questions are answered, athletes are left to weigh the theoretical risks against the practical benefits.
Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.